Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Breathe Biologics, a subsidiary of TSOI, has announced promising data regarding a novel cellular therapy targeting Chronic Obstructive Pulmonary Disease (COPD).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Breathe
The Company disclosed that administration of monocytic progenitors derived from umbilical cord blood treated under proprietary conditions were able to reduce inflammation and preserve lung function in the elastase mediated animal model of COPD. The cellular product possessed characteristics of pulmonary progenitor cells combined with immune regulatory myeloid suppressor cells.
Furthermore, it was demonstrated that blockade of the cytokine’s interleukin-10 and/or interleukin-17 negated the therapeutic effect of the cells, thus suggesting a possible mechanism of action for this novel cellular therapy.
“As a physician who has witnessed firsthand the dismal lack of options in treatment of advanced COPD, and based on our preclinical animal data, I am eager to work with regulators in accelerating translation from the bench to the clinic,” said Dr.
Breathe Biologics is developing the use of JadiCells, a stem cell product in Phase III for COVID ARDS, for the treatment of COPD under IND# 28508. Breathe Biologics has acquired the IND from
“The beauty of running a biotechnology company in the
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005599/en/
ir@tsoimail.com
Source: